首页> 外文期刊>Vaccine >Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design
【24h】

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design

机译:在不同的MERS冠状病毒受体结合片段中寻找理想的疫苗候选者-免疫聚焦在亚单位疫苗设计中的重要性

获取原文
获取原文并翻译 | 示例
           

摘要

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is currently spreading among humans, making development of effective MERS vaccines a high priority. A defined receptorbinding domain (RBD) in MERS-CoV spike protein can potentially serve as a subunit vaccine candidate against MERS-CoV infections. To identify an ideal vaccine candidate, we have constructed five different versions of RBD fragments, S350-588-Fc, S358-588-Fc, S367-588-Fc, S367-606-Fc, and S377-588-Fc (their names indicate their residue range in the spike protein and their C-terminal Fc tag), and further investigated their receptor binding affinity, antigenicity, immunogenicity, and neutralizing potential. The results showed that S377-588-Fc is among the RBD fragments that demonstrated the highest DPP4binding affinity and induced the highest-titer IgG antibodies in mice. In addition, S377-588-Fc elicited higher-titer neutralizing antibodies than all the other RBD fragments in mice, and also induced high-titer neutralizing antibodies in immunized rabbits. Structural analysis suggests that S377-588-Fc contains the stably folded RBD structure, the full receptor-binding site, and major neutralizing epitopes, such that additional structures to this fragment introduce non-neutralizing epitopes and may also alter the tertiary structure of the RBD. Taken together, our data suggest that the RBD fragment encompassing spike residues 377-588 is a critical neutralizing receptor-binding fragment and an ideal candidate for development of effective MERS vaccines, and that adding non-neutralizing structures to this RBD fragment diminishes its neutralizing potential. Therefore, in viral vaccine design, it is important to identify the most stable and neutralizing viral RBD fragment, while eliminating unnecessary and non-neutralizing structures, as a means of "immunofocusing"
机译:新近出现的中东呼吸综合征冠状病毒(MERS-CoV)目前正在人类中传播,这使得开发有效的MERS疫苗成为当务之急。 MERS-CoV穗蛋白中定义的受体结合结构域(RBD)可以潜在地用作抗MERS-CoV感染的亚单位疫苗候选物。为了确定理想的候选疫苗,我们构建了五个不同版本的RBD片段:S350-588-Fc,S358-588-Fc,S367-588-Fc,S367-606-Fc和S377-588-Fc(它们的名称)表示它们在刺突蛋白及其C端Fc标签中的残基范围),并进一步研究了它们的受体结合亲和力,抗原性,免疫原性和中和潜力。结果表明,S377-588-Fc是RBD片段之一,其在小鼠中表现出最高的DPP4结合亲和力并诱导最高的IgG抗体。此外,S377-588-Fc在小鼠中引起的滴度更高的中和抗体比所有其他RBD片段高,并且在免疫兔子中也诱导了高滴度的中和抗体。结构分析表明,S377-588-Fc包含稳定折叠的RBD结构,完整的受体结合位点和主要中和表位,因此该片段的其他结构会引入非中和表位,并且还可能改变RBD的三级结构。综上所述,我们的数据表明,包含尖峰残基377-588的RBD片段是关键的中和受体结合片段,是开发有效MERS疫苗的理想候选者,向该RBD片段添加非中和结构会削弱其中和潜力。 。因此,在病毒疫苗设计中,重要的是鉴定最稳定和中和的病毒RBD片段,同时消除不必要的和非中和的结构,以此作为“免疫聚焦”手段

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号